News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Advisory Panel to Review Medtronic, Inc. (MDT)'s Endeavor Drug Eluting Stent on October 10


9/12/2007 9:31:42 AM

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT), announced today that a U.S. Food and Drug Administration (FDA) Advisory Panel will review the Premarket Approval (PMA) application for the company’s Endeavor® Drug Eluting Coronary Stent on October 10. The FDA’s Circulatory System Devices Panel is scheduled to meet October 10 and 11. Endeavor is the only drug eluting stent on the agenda for review during the October 10 panel meeting.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES